Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Impact of FDG-labelled positron emission tomography imaging on the management of non-small-cell lung cancer
Autore:
Salminen, E; Mac Manus, M;
Indirizzi:
Turku Univ Hosp, Dept Radiotherapy & Oncol, Turku, Finland Turku Univ Hosp Turku Finland Dept Radiotherapy & Oncol, Turku, Finland Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia Peter MacCallum Canc Inst Melbourne Vic Australia 3000 ic 3000, Australia
Titolo Testata:
ANNALS OF MEDICINE
fascicolo: 6, volume: 33, anno: 2001,
pagine: 404 - 409
SICI:
0785-3890(200109)33:6<404:IOFPET>2.0.ZU;2-8
Fonte:
ISI
Lingua:
ENG
Soggetto:
F-18 FLUORODEOXYGLUCOSE; COMPARATIVE EFFICACY; PET; METASTASES; CARCINOMA; ONCOLOGY; SURVIVAL; PROJECT;
Keywords:
FDG-PET; fluorodeoxyglucose; non-small-cell lung cancer; outcome; staging; treatment;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
49
Recensione:
Indirizzi per estratti:
Indirizzo: Salminen, E Turku Univ Hosp, Dept Radiotherapy & Oncol, Kiinamyllynkatu 4-8, Turku, Finland Turku Univ Hosp Kiinamyllynkatu 4-8 Turku Finland u, Finland
Citazione:
E. Salminen e M. Mac Manus, "Impact of FDG-labelled positron emission tomography imaging on the management of non-small-cell lung cancer", ANN MED, 33(6), 2001, pp. 404-409

Abstract

Lung cancer is currently the leading cause of cancer-related death in bothmen and women in most Western countries. Although 5-year survival rates have doubled from 1960s, they are low compared with survival rates for other cancer types. Tumour stage is the strongest prognostic factor and the most important parameter that guides treatment decision making. Metabolic imaging with fluorodeoxyglucose-labelled positron emission tomography (FDG-PET) has proved superior to conventional imaging for staging of non-small-cell lung cancer. This new imaging modality permits more accurate planning of treatment with surgery and radiotherapy and provides information of greater prognostic significance than what can be obtained with conventional approaches. FDG-PET has been approved in the USA and the UK as a basic and invaluabletool in the management of lung cancer. This paper reviews current trends in clinical practice on the applications of FDG-PET in the management of non-small-cell lung cancer.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/04/20 alle ore 07:22:48